Predicting Drug Response with Lung Cancer Tumor Replica Platform
A new study introduces an ex vivo platform that uses 3D lung tumor replicas to test drug responses directly, aiming to improve precision oncology. This method seeks to overcome the limitations of genomic profiling by providing functional testing for personalized treatment.
Why it matters
This technology could significantly improve lung cancer treatment outcomes by identifying effective therapies faster than traditional genomic methods.
Precision oncology has transformed lung cancer care, but its reach remains uneven. Targeted therapies and immunotherapies have improved outcomes for selected patients, yet many people with lung cancer still receive systemic treatment without a reliable way to know whether their tumor will respond.
The article provides a technical overview of a medical study without editorializing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in